Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytalux (pafolacianine) for Intraoperative Imaging of Prostate Cancer
NCT06434909Phase 2Completed
- Sponsor
- Indiana University
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of pafolacianine in prostate cancer (PCa), sponsored by Indiana University. Started Sep 2024; status: completed.
02
Drugs
pafolacianine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06434909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434909.